TocilizumabV1, Istex, Curation, indexHead, KwdEn.i

Index : Keywords

Les termes de plus forte occurence

123	Rheumatoid arthritis
39	Tocilizumab
21	Interleukin-6
21	Biologics
20	IL-6
15	Juvenile idiopathic arthritis
14	Inflammation
13	Rituximab
12	Therapy
12	Infliximab
12	Etanercept
11	Methotrexate
11	Cytokines
10	Treatment
9	Systemic lupus erythematosus
9	Disease activity
8	Prognosis
8	Immunosuppression
8	Biologicals
8	Arthritis
7	Tumor necrosis factor-alpha
7	Osteoporosis
7	Disease-modifying antirheumatic drugs
7	Cytokine
7	Biological agents
7	Ankylosing spondylitis
6	rheumatoid arthritis
6	Vaccination
6	Glucocorticoids
6	Giant cell arteritis
6	Autoimmune diseases
5	Vasculitis
5	Still’s disease
5	Histology
5	Autoimmunity
5	Autoantibodies
5	Adalimumab
4	Synovium
4	Rheumatology
4	Interleukin-6 receptor
4	Infection
4	Hepcidin
4	DMARD
4	Crohn’s disease
4	Cancer
4	Antirheumatic agents
4	Anemia
4	Adult-onset Still’s disease
4	AA amyloidosis
3	Uveitis
3	Tumor necrosis factor-α
3	Tuberculosis
3	TNF-α
3	TNF, tumour necrosis factor
3	TNF inhibitors
3	Synovitis
3	Rheumatic diseases
3	Review
3	Relapsing polychondritis
3	Pharmacokinetics
3	Mycophenolate mofetil
3	Monoclonal antibodies
3	Meta-analysis
3	Macrophage activation syndrome
3	MRA
3	Lupus nephritis
3	Interleukin-1
3	Efficacy
3	Diagnosis
3	Diagnosis-related groups
3	Corticosteroids
3	Collagen-induced arthritis
3	Coding
3	Classification
3	Chemokines
3	Castleman’s disease
3	Biological therapy
3	Atherosclerosis
3	Arthritis, rheumatoid
3	Antibodies
3	Anti-TNF therapy
3	Amyloidosis
3	Adult onset Still’s disease
3	Additional payments
3	Abatacept
2	tocilizumab
2	mRNA display
2	inflammation
2	disease activity
2	anti-TNF
2	Ulcerative colitis
2	Type 2 diabetes
2	Treatment outcome
2	Targeted therapy
2	Target-mediated drug disposition
2	Takayasu’s arteritis
2	Takayasu arteritis
2	TNFα
2	TNFα blockers
2	TNF-alpha inhibitors
2	TNF blockers
2	Systemic sclerosis
2	Systematic review
2	Spondyloarthritis
2	Signal transduction
2	STAT3
2	SLE
2	Risk
2	Rheumatoid factor
2	Rheumatic disease
2	Renal function
2	Remission
2	Registry
2	Registries
2	Recommendations
2	RA, rheumatoid arthritis
2	Quantification
2	Pulmonary arterial hypertension
2	Psoriatic arthritis
2	Psoriasis
2	Prevention
2	Pregnancy
2	Polyneuropathy
2	Pharmacovigilance
2	Pathogenesis
2	PET
2	Oxidative stress
2	Outcome
2	Off-label use
2	Obesity
2	Neuromyelitis optica
2	Nervous system
2	Nephritis
2	Mechanism of action
2	MTX, methotrexate
2	Lupus erythematosus, systemic
2	Leflunomide
2	Joint destruction
2	Iron
2	Iron deficiency
2	Interleukin-6 (IL-6)
2	Innate immunity
2	Inflammatory mediators
2	Infections
2	Immunogenicity
2	Immunity
2	Hyperthermia
2	Hospital financing
2	Glucocorticosteroids
2	Foot
2	Fibrosis
2	Fever
2	Fatigue
2	Familial Mediterranean fever
2	Erythema nodosum
2	Erosions
2	Epidemiology
2	Early diagnosis
2	Drug therapy
2	Disease modifying antirheumatic drugs
2	Differential diagnosis
2	Diagnostics
2	Depression
2	DMARDs
2	DMARDS
2	Cost-effectiveness
2	Congestive heart failure
2	Complement
2	Childhood
2	Child
2	Cardiovascular risk
2	Cardiovascular disease
2	Bone
2	Bone mineral density
2	Biological drugs
2	Biologic therapies
2	Biologic drugs
2	Belimumab
2	Behçet’s disease
2	Anti-inflammatory agents, non-steroidal
2	Anakinra
2	Adult-onset Still's disease
2	Adenosine deaminase
2	ANCA
2	ACR, American College of Rheumatology
1	v-myc
1	transforming growth factor beta
1	total joint arthroplasty
1	toll-like receptor-9
1	therapy
1	therapeutic monoclonal antibody
1	sgp130
1	serum half-life
1	sIL-6R
1	sCD163
1	rs8192284 IL6R polymorphism
1	regeneration
1	recent developments
1	protein engineering
1	pharmacokinetics
1	periprosthetic joint infection
1	pegylation
1	p53
1	p300
1	osteoclasts
1	optimal design
1	non-linear mixed effects model
1	monitoring
1	magnetic field
1	latency-associated peptide
1	juvenile idiopathic arthritis
1	joint damage
1	iron
1	intravenous immunoglobulin
1	interleukin-6
1	interleukin-18
1	interleukin 6
1	interleukin 18
1	inflammatory bowel disease
1	inflammatory arthritis
1	indications
1	immunogenicity
1	immune-mediated inflammatory disease
1	humanized anti-IL-6 receptor antibody
1	hepcidin
1	hemoglobin
1	gp80
1	gp130
1	glycoengineering
1	glial scar
1	familial cold autoinflammatory syndrome
1	efficacy
1	drug metabolism
1	display technology
1	cytokines
1	cryopyrin
1	corticosteroids
1	cholinergic pathway
1	cancer
1	cancer chemotherapy
1	cIAP-2
1	c-Fos
1	c-Fos/AP-1
1	biosimilar
1	biopharmaceutical drug
1	biologics
1	biological therapies
1	biobetter
1	bcl-2 therapy
1	bayesian fisher information matrix
1	autoimmune disease
1	articular erosion
1	antirheumatic drugs
1	anti-TNF therapy
1	anti-IL-6R (tocilizumab)
1	anti-IL-6 receptor monoclonal antibody
1	adult-onset Still’s disease
1	adalimumab
1	Yamaguchi criteria
1	Wound infections
1	White blood cell count
1	Wegener’s granulomatosis
1	Volumetry
1	Virtual screening
1	Viral infection
1	Venous thromboembolism
1	Vasoactive drugs
1	Vasculitides
1	Vaccine
1	VEGF
1	Urtica dioica
1	Undesired side effects
1	Ultrasound
1	Ultrasonography
1	Ultrasonography of joint
1	UV exposure
1	UC, ulcerative colitis
1	Tumour
1	Tumour-necrosis-factor-alpha-inhibitor
1	Tumour necrosis factor alpha
1	Tumor necrosis factor
1	Tumor necrosis factor-alpha inhibitors
1	Tumor necrosis factor-alpha inhibitor
1	Tumor necrosis factor inhibitors
1	Tubule formation
1	Tryptophan
1	Tripterygium wilfordii
1	Triple DMARD therapy
1	Treatment access
1	Travel
1	Transmeridian travel
1	Transition to adult care
1	Transcription factors
1	Toll-like receptors
1	Tolerability
1	Tofacitinib
1	Tissue repair
1	Thrombotic thrombocytopenic purpura
1	Three-dimensional volumetric ultrasonography
1	Therapy interval
1	Therapeutische Antikörper
1	Therapeutic strategy
1	Therapeutic strategies and options
1	Therapeutic antibodies
1	Th17 cells
1	Terminal illness
1	Teriparatide
1	Teratogenicity
1	Temporal arteries
1	Targeted immunotherapy
1	Targeted immune modulators
1	Targeted drug delivery
1	Takayasu's arteritis
1	Tacrolimus
1	TNFα, tumour necrosis factor-α
1	TNF
1	TNF-α-antagonists
1	TNF-α inhibitors
1	TNF-α antagonists
1	TNF-failure
1	TNF receptors
1	TNF inhibitor
1	THP-1 cells
1	TB, tuberculosis
1	T-cell lymphoma
1	T cell
1	Systemic reactive AA amyloidosis
1	Systemic onset juvenile idiopathic arthritis
1	Systemic lupus erythematosus (SLE)
1	Systemic juvenile idiopathic arthritis
1	Systemic inflammatory disorder
1	Systemic idiopathic juvenile arthritis
1	Systemic diseases
1	Systemic JIA
1	Systematic literature research
1	Synoviocytes
1	Synovial membrane
1	Synovial fluid
1	Switching
1	Switch treatment
1	Survival rate
1	Survey
1	Surgery
1	Surface chemistry
1	Suppurative arthritis
1	Subcutaneous
1	Stromal cells
1	Stratification
1	Strategy
1	Still’s exanthema
1	Stiff person syndrome
1	Standard vaccinations
1	Stability
1	Spontaneous reporting
1	Spondylitis, ankylosing
1	Splenectomy
1	Spinal cord injury
1	Sonography
1	Soluble and membrane-bound targets
1	Solid support characterization
1	Soft tissue tumor
1	Slicing of indications
1	Sjögren’s syndrome
1	Size
1	Single nucleotide polymorphisms
1	Siltuximab
1	Silicone
1	Signaling
1	Signaling inhibitors
1	Sickness behavior
1	Shared epitope
1	Shape
1	Serum amyloid A
1	Serum amyloid P
1	Serotonin
1	Septic arthritis
1	Secondary amyloidosis
1	Search engines
1	Screening
1	Scoring systems
1	Sclerostin
1	Sclerosis, systemic
1	Scleroderma
1	Scleroderma, systemic
1	Sciatica
1	Scalp necrosis
1	Satisfaction with life
1	Safety
1	Safety profile
1	SONIC, SONIC (Study Of biologic and Immunomodulator Naive patients in Crohn’s disease
1	SNP
1	SF-36
1	SAA1.3 allele
1	S100 proteins
1	Risk patients
1	Risk of infection
1	Risedronate
1	Rilonacept
1	Rheumatoid
1	Rheumatoid vasculitis
1	Rheumatoid disorders
1	Rheumatoid Arthritis
1	Revision arthroplasty
1	Reumatoid arthritis
1	Respiratory involvement
1	Resistant disease
1	Renoprotective potential
1	Renal insufficiency
1	Renal failure
1	Relapsing polychondritis disease activity index
1	Regulatory authorities
1	Regulatory T cells
1	Regression
1	Regression of amyloid
1	Regression analysis
1	Refractory disease
1	Refractory arthritis
1	Recommendation
1	Receptors
1	Receptors, tumor necrosis factor/therapeutic use
1	Reader protein
1	Reactive oxygen species
1	Reactive amyloidosis
1	Re-administration
1	Raynaud disease
1	Random peptide
1	Radiographic parameter
1	RCT, randomised controlled trial
1	RAW 264.7 (mouse leukemic monocyte macrophage cell line)
1	RANKL
1	Quasi-steady-state approximation
1	Quantitative structure–activity relationship (QSAR)
1	Quantitative analysis
1	Quality-of-life measurement
1	QoL, quality of life
1	Puromycin
1	Pulmonary rheumatoid nodule
1	Psoriatic
1	Pseudofolliculitis
1	PsA, psoriatic arthritis
1	Protein stability
1	Prosthesis
1	Prosthesis loosening
1	Prostate cancer
1	Prophylaxis
1	Proinflammatory cytokines
1	Product surveillance, Postmarketing/statistics & numerical data
1	Pro-inflammatory cytokine
1	Primary vasculitis of the central nervous system
1	Primary immune surveillance
1	Primary headaches
1	Prevention of infection
1	Prevalence
1	Pregnancy complications
1	Prediction
1	Power Doppler
1	Power Doppler ultrasonography
1	Portuguese Caucasian
1	Portugal
1	Pompe’s disease
1	Polymyositis
1	Polymorphism
1	Polyglandular autoimmune syndrome
1	Polychondropathia
1	Polychondritis
1	Polyarthritis
1	Pneumocystis pneumonia
1	Pneumococcus
1	Plazentarer IgG-Transport
1	Platinum resistance
1	Platelets
1	Plasma cell type Castleman’s disease
1	Placental IgG-transport
1	Physical therapy
1	Pharmacokinetic properties
1	Pharmacogenomics
1	Pharmacogenetics
1	Pharmacodynamics
1	Personalized healthcare
1	Periprosthetic joint infection
1	Peripheral rheumatoid nodule
1	Perioperative management
1	Periodic syndrome
1	Pemphigus
1	Pemphigus foliaceus
1	Pediatric rheumatology
1	Patient care management
1	Paraprotein
1	Pain
1	PRECISE, PEGylated antibody fRagment Evaluation in. Crohn’s disease: Safety and Efficacy
1	PPD, partial purified derivative
1	PEG, polyethylene glycol
1	PDUS
1	P38 MAPK
1	Ozone
1	Overproduction
1	Ovarian carcinoma
1	Outcomes
1	Outcomes research
1	Osteolysis, essential

Manipulations en shell (Unix/Dilib)

HfdCat /Users/jacquesducloy/Documents/WicriRoot/Wicri/Sante/explor/Tocilizumab.storage/TocilizumabV1/Data/Istex/Curation/KwdEn.i.hfd| SxmlCut idx/l | grep ...

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021

	Serveur d'exploration Tocilizumab - Curation (Istex) Index « Mots-clés originaux en anglais » - tête de navigation
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Tocilizumab - Curation (Istex)Index « Mots-clés originaux en anglais » - tête de navigation

Index : Keywords

Les termes de plus forte occurence

Manipulations en shell (Unix/Dilib)

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « Mots-clés originaux en anglais » - tête de navigation